Bifunctional iRGD-anti-CD3 enhances antitumor potency of T cells by facilitating tumor infiltration and T-cell activation

BACKGROUND: Poor infiltration and limited activation of transferred T cells are fundamental factors impeding the development of adoptive cell immunotherapy in solid tumors. A tumor-penetrating peptide iRGD has been widely used to deliver drugs deep into tumor tissues. CD3-targeting bispecific antibo...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Immunother Cancer
Prif Awduron: Zhou, Shujuan, Meng, Fanyan, Du, Shiyao, Qian, Hanqing, Ding, Naiqing, Sha, Huizi, Zhu, Mei, Yu, Xiaoxiao, Wang, Lifeng, Liu, Baorui, Wei, Jia
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BMJ Publishing Group 2021
Pynciau:
Immune Cell Therapies and Immune Cell Engineering
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC8126316/
https://ncbi.nlm.nih.gov/pubmed/33986122
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001925
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg